These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6594241)

  • 1. VP 16-213 and cytosine-arabinoside combination chemotherapy for refractory acute lymphoblastic leukemia in adults.
    Morra E; Lazzarino M; Alessandrino EP; Inverardi D; Canevari A; Bernasconi C
    Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1471-5. PubMed ID: 6594241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia.
    Whitlock JA; Wells RJ; Hord JD; Janco RL; Greer JP; Gay JC; Edwards JR; McCurley TL; Lukens JN
    Leukemia; 1997 Feb; 11(2):185-9. PubMed ID: 9009078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide and cytosine arabinoside combination chemotherapy for refractory acute lymphocytic leukemia in childhood.
    Esumi N; Todo S; Arakawa S; Imashuku S
    J Clin Oncol; 1986 Jul; 4(7):1089-93. PubMed ID: 3459812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.
    Vogler WR; McCarley DL; Stagg M; Bartolucci AA; Moore J; Martelo O; Omura GA
    Leukemia; 1994 Nov; 8(11):1847-53. PubMed ID: 7967730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
    Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
    J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of cytosine arabinoside, carboplatin and etoposide chemotherapy in the treatment of relapsing and refractory non-Hodgkin's lymphoma.
    Niitsu N; Umeda M
    Acta Haematol; 1996; 96(1):36-40. PubMed ID: 8677759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
    Hiddemann W; Büchner T; Heil G; Schumacher K; Diedrich H; Maschmeyer G; Ho AD; Planker M; Gerith-Stolzenburg S; Donhuijsen-Ant R
    Leukemia; 1990 Sep; 4(9):637-40. PubMed ID: 2395383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I-II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute non-lymphocytic leukemia.
    Bishop JF; Joshua DE; Lowenthal RM; Kronenberg H; Whiteside MG; Cobcroft R; Dodds A; Wolf M; Manoharan A
    Aust N Z J Med; 1986 Feb; 16(1):48-51. PubMed ID: 3458446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
    Velasquez WS; McLaughlin P; Tucker S; Hagemeister FB; Swan F; Rodriguez MA; Romaguera J; Rubenstein E; Cabanillas F
    J Clin Oncol; 1994 Jun; 12(6):1169-76. PubMed ID: 8201379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia.
    Lambertenghi-Deliliers G; Maiolo AT; Annaloro C; Cortelezzi A; Pogliani E; Ganzina F; Polli EE
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):1041-5. PubMed ID: 3478198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose ara-C and etoposide in refractory or relapsing acute leukemia.
    Freund M; Link H; Diedrich H; LeBlanc S; Wilke HJ; Poliwoda H
    Cancer Chemother Pharmacol; 1991; 28(6):487-90. PubMed ID: 1934254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose cytosine arabinoside and etoposide in the treatment of relapsed or refractory adult leukemia.
    Gryn J; Conroy J; Topolsky D; Crilley P; Kahn SB; Bulova S; Weiss J; Brodsky I
    Am J Clin Oncol; 1991 Feb; 14(1):52-4. PubMed ID: 1987740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia.
    Liso V; Specchia G; Capalbo S; Pavone V; Iacobazzi A; Iaculli ML; Dione R; Pansini N
    Acta Haematol; 1992; 87(1-2):54-7. PubMed ID: 1585771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
    Gaspard MH; Maraninchi D; Stoppa AM; Gastaut JA; Michel G; Tubiana N; Blaise D; Novakovitch G; Rossi JF; Weiller PJ
    Cancer Chemother Pharmacol; 1988; 22(3):256-62. PubMed ID: 3044633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
    Esumi N; Todo S; Arakawa S; Imashuku S
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):951-8. PubMed ID: 3963859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.
    Kantarjian HM; Estey EH; Plunkett W; Keating MJ; Walters RS; Iacoboni S; McCredie KB; Freireich EJ
    Am J Med; 1986 Sep; 81(3):387-94. PubMed ID: 3463209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study on regimen cyclophosphamide, Ara-C and topotecan (CAT) in treatment of patients with refractory or relapsed acute myelogenous leukemia].
    Qin TJ; Xu ZF; Wang JY; Zhou CL; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1342-6. PubMed ID: 19840480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
    Paciucci PA; Cuttner J; Holland JF
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):36-40. PubMed ID: 6385264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.